DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

23 9 2024 09:50:55 提供 Nasdaq GlobeNewswire

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

13 8 2024 16:05:00 提供 Nasdaq GlobeNewswire

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

30 7 2024 16:00:00 提供 Nasdaq GlobeNewswire

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

28 6 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in June

30 5 2024 16:30:00 提供 Nasdaq GlobeNewswire

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

14 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Dyadic to Attend Industry and Investor Events in May

08 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

30 4 2024 16:30:00 提供 Nasdaq GlobeNewswire

Dyadic Reports 2023 Full Year Results and Recent Company Progress

28 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Dyadic Announces Change in Board and Management Leadership Roles

28 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in April

27 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

26 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

21 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

14 3 2024 16:30:00 提供 Nasdaq GlobeNewswire

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 3 2024 09:57:14 提供 Nasdaq GlobeNewswire

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in March

01 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

28 2 2024 08:30:00 提供 Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

23 2 2024 02:00:00 提供 Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

21 2 2024 08:30:00 提供 Nasdaq GlobeNewswire